Expression And Clinical Significance Of ERCC1 And TUBB3 In Gastric Carcinoma

Objective:Gastric cancer is one of the most common malignant tumors of the gastrointestinal tract in the world.It mainly originated from a kind of malignant tumor of gastric mucosa epithelial cells.Early diagnosis of gastric cancer is often lack of typical performance.Most of them are in late stage of discovery,thus missing the optimal timing of treatment.Chemotherapy is the main adjuvant treatment of gastric cancer after surgery,especially the high degree of malignancy of the pathological type;lesions greater than 5cm,multiple lesions and patients younger than 45 years of age,can significantly prolong the survival of patients.However,different individuals often have different effects on the same chemotherapy regimens and toxic side effects.In order to improve the curative effect of chemotherapy,reduce the toxic and side effects of patients and improve the quality of life of patients,we detected the expression of ERCC1 and TUBB3 by detecting the nucleotide excision in gastric cancer tissues,Repair of cross-complementary gene 1 pairs of platinum-based chemotherapy drugs andβ-tubulinⅢpaclitaxel chemotherapeutic drugs chemotherapy prognosis,in order to find the basis for the selection of the best chemotherapy,In order to improve the prognosis of patients with chemotherapy.Methods:83 patients with stageⅡ-Ⅲgastric cancer who underwent radical gastrectomy in Lu’an Hospital of Anhui Medical University from April 2011 to April 2014 were collected,and 6 cycles of DCF regimen were given after the operation.Immunohistochemistry was used to detect the expression of ERCC1andβ-tubulinⅢin each gastric cancer tissue specimens.The expression of ERCC1 andβ-tubulinⅢin patients with gastric cancer was analyzed.Pathological features and the relationship between the prognosis of chemotherapy.Results:Among 83 gastric cancer patients,35 cases(42.2%)had ERCC1 overexpression and 29(34.9%)had high TUBB3 expression.The expression of ERCC1 and TUBB3 had no significant correlation with gender,age,clinical stage,differentiation,tumor location,depth of invasion,Lauren classification,lymph node metastasis,vascular tumor thrombus and nerve bundle invasion(P>0.05).ERCC1 and TUBB3,patients with low expression had longer disease-free survival(31.5 months vs 11 months vs 30 months vs14 months)than those with high expression(χ~2=8.123,P=0.004;χ~2=5.619,P=0.018),3-year overall survival[75.0%(36/48):40.0%(14/35);72.2%(39/54):37.9%(11/29)]There was statistical significance(χ~2=10.352,P=0.001;χ~2=5.619,P=0.018).After further subgroup analysis,we found that in patients with stage II gastric cancer,patients with higher expression of TUBB3 had longer disease-free survival(36 months vs 24 months),the difference was statistically significant(χ~2=3.838,P=0.050).Among patients with stage III gastric cancer,patients with higher expression of ERCC1 had a longer disease-free survival(25 months vs 9 months)and a 3-year overall survival rate of 67.7%(21/31):28.0%(7/25)]was significantly higher than that in patients with low expression of TUBB3(χ~2=7.043,P=0.008;χ~2=8.743,P=0.003);patients with higher expression of TUBB3 also had longer disease-free survival(22.5 months vs 10 months)and higher 3-year overall survival rate(65.8%(25/38):27.8%(5/18)],the difference was statistically significant(χ~2=3.902,P=0.048;χ~2=7.096,P=0.008).Conclusion:The expression levels of ERCC1 and TUBB3 in gastric cancer tissues can predict the prognosis of DCF adjuvant chemotherapy in patients with gastric cancer,and can be used as the efficacy index of DCF chemotherapy.Patients with low expression of ERCC1 and TUBB3 had longer disease-free survival and higher 3 year survival rates.